1. A236 ASSOCIATION OF STOOL METABOLOMIC PROFILE AND MICROBIOME COMPOSITION RISK SCORE WITH FUTURE ONSET OF CROHN'S DISEASE. (21st February 2022) Authors: Lee, S; Raygoza Garay, J; Turpin, W; Smith, M I; Goethel, A; Griffiths, A; Moayyedi, P; Espin-Garcia, O; Aumais, G; Bernstein, C N; Avni-Biron, I; Cino, M; Deslandres, C; Dotan, I; El-Matary, W; Feagan, B G; Guttmen, D S; Huynh, H Q; Hyams, J; Jacobson, K Journal: Journal of the Canadian Association of Gastroenterology Issue: Volume 5(2022)Supplement 1 Page Start: 127 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. DOP008 Safety of adalimumab in children and adolescents with moderate-to-severe Crohn's disease: interim results of the CAPE registry. (16th January 2018) Authors: Turner, D; Koletzko, S; Winter, H; Baldassano, R; Dubinsky, M; Faubion, W; Hyams, J; Kugathasan, S; Rosh, J; Escher, J; Griffiths, A; Kierkus, J; Russell, R; Heap, G; Arikan, D; Kuehnl, V; Petersson, J; Robinson, A; Ruemmele, F Journal: Journal of Crohn's and colitis Issue: Volume 12:Number 1(2018:Jan.)Supplement 1 Page Start: S035 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Faecal calprotectin, lactoferrin, M2-pyruvate kinase and S100A12 in severe ulcerative colitis: a prospective multicentre comparison of predicting outcomes and monitoring response. Issue 9 (26th August 2010) Authors: Turner, D; Leach, S T; Mack, D; Uusoue, K; McLernon, R; Hyams, J; Leleiko, N; Walters, T D; Crandall, W; Markowitz, J; Otley, A R; Griffiths, A M; Day, A S Journal: Gut Issue: Volume 59:Issue 9(2010) Page Start: 1207 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. OP05 Outcome of induction therapy with vedolizumab in children: Results from the prospective, multi-centre VEDOKIDS study. (21st January 2022) Authors: Shavit, Z; Stein, R; Aloi, M; Ledder, O; Focht, G; Urlep, D; Hyams, J; Broide, E; Vais, B; Levine, J; Shouval, D; Matar, M; Assa, A; Rosh, J; Hussey, S; Markowitz, J; Yerushalmy-Feler, A; Miele, E; Shaoul, R; Russell, R K Journal: Journal of Crohn's and colitis Issue: Volume 16(2022)Supplement 1 Page Start: i005 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. OP32 Stool microbiome communities predict remission in treatment-naïve Pediatric Crohn's Disease patients. (27th May 2021) Authors: Verburgt, C; Dunn, K; Bielawski, J; Otley, A; Heyman, M; Sunseri, W; Shouval, D; Levine, A; de Meij, T; Hyams, J; Denson, L; Kugathasan, S; Benninga, M; de Jonge, W; Van Limbergen, J Journal: Journal of Crohn's and colitis Issue: Volume 15(2021)Supplement 1 Page Start: S030 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. P089 Long ncRNA Landscape in the Rectum of Treatment Naïve Early Onset Ulcerative Colitis Highlights Association with Severity and Early and Late Disease Outcome, with Potential Role in Epithelial Metabolic Functions. (21st January 2022) Authors: Haberman Ziv, Y; Braun, T; Sosnovski, K; Amir, A; VanDussen, K; Igor Ulitsky, I U; Griffiths, A; Walters, T; Mack, D; Boyle, B; Kugathasan, S; Jegga, A; Hyams, J; Denson, L Journal: Journal of Crohn's and colitis Issue: Volume 16(2022)Supplement 1 Page Start: i187 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. P396 Pharmacokinetics, immunogenicity and clinical outcomes of golimumab from the PURSUIT PEDS ulcerative colitis study long-term (through week 126) extension. (16th January 2018) Authors: Hyams, J; O'Brien, C D; Padgett, L; Rosh, J; Turner, D; Veereman, G; Griffiths, A; Heyman, M B; Wahbeh, G; Adedokun, J; Strauss, R; Chan, D; Lynch, J Journal: Journal of Crohn's and colitis Issue: Volume 12:Number 1(2018:Jan.)Supplement 1 Page Start: S304 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. P651 Disease severity and intensity of therapy predicts serious adverse events in paediatric ulcerative colitis: the DEVELOP experience. (25th January 2019) Authors: Winter, H; Izanec, J; Busse, C; Wang, Y; Hyams, J Journal: Journal of Crohn's and colitis Issue: Volume 13(2019)Supplement 1 Page Start: S445 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. P700 The GEM Project: Stool metabolomic profile is associated with microbiome risk score and with future onset of Crohn's disease in healthy first-degree relatives. (21st January 2022) Authors: Lee, S H; Raygoza Garay, J A; Turpin, W; Smith, M I; Goethel, A; Griffiths, A; Moayyedi, P; Espin-Garcia, O; Abreu, M; Aumais, G; Bernstein, C N; Biron, I; Cino, M; Deslandres, C; Dotan, I; El-Matary, W; Feagan, B; Guttman, D; Huynh, H; Hyams, J Journal: Journal of Crohn's and colitis Issue: Volume 16(2022)Supplement 1 Page Start: i596 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. P774 Maintenance treatment with vedolizumab in children with Inflammatory Bowel Disease: follow-up results from the prospective multicenter VEDOKIDS study. (30th January 2023) Authors: Atia, O; Shavit-Brunschwig, Z; Quteineh, A; Lev-Tzion, R; Stein, R; Broide, E; Urlep, D; Hyams, J; Aloi, M; Shouval, D S; Assa, A; Hussey, S; Markowitz, J; Yerushalmy, A; Miele, E; Russell, R K; Turner, D Journal: Journal of Crohn's and colitis Issue: Volume 17(2023)Supplement 1 Page Start: i904 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗